Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Taxus Pharmaceuticals Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Taxus Pharmaceuticals Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Taxus Pharmaceuticals Holdings. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Taxus Pharmaceuticals Holdings's
is considered below, and whether this is a fair price.
Price based on past earnings
Taxus Pharmaceuticals Holdings's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Taxus Pharmaceuticals Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Specialty Retail industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Taxus Pharmaceuticals Holdings
expected to grow at an
Unable to compare Taxus Pharmaceuticals Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Taxus Pharmaceuticals Holdings's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Taxus Pharmaceuticals Holdings's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Taxus Pharmaceuticals Holdings is high growth as no earnings estimate data is available.
Unable to determine if Taxus Pharmaceuticals Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Taxus Pharmaceuticals Holdings's filings and announcements here.
Taxus Pharmaceuticals Holdings's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Taxus Pharmaceuticals Holdings
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Taxus Pharmaceuticals Holdings's finances.
The net worth of a company is the difference between its assets and liabilities.
Taxus Pharmaceuticals Holdings's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Taxus Pharmaceuticals Holdings has no long term commitments.
This treemap shows a more detailed breakdown of
Taxus Pharmaceuticals Holdings's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Taxus Pharmaceuticals Holdings has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Jiayue Zhang serves as Chief Executive Officer, President and Chief Financial Officer at Taxus Pharmaceuticals Holdings, Inc. Mr. Zhang serves as Chairman of the Board, Chief Executive Officer and President of Taxus Pharmaceuticals, Inc. (formerly, Shanxi Taxus Pharmaceuticals Co. Ltd.). He serves as President of Shenzhen Frontsea Taxus Industry Capital Management. He has been an Executive Chairman of Taxus Cardium Pharmaceuticals Group, Inc. since January 2015. From February 1975 to December 1976, he worked in Shanxi Yuci Steel Plant; from January 1977 to December 1979, he served as officers in the People’s Liberation Army of China; from January 1980 to July 1982, he served in Shanxi Province Medicine and Pharmaceutical Company, Yuci Branch; from August 1982 to August 1985, he served as administrative staff at Shanxi Chinese Medicine School; from September 1985 to April 1992, he served as the Director of Yuci Pharmaceutical Plant; from May 1992 to July 1993, he served as the Director of Shanxi Medicine and Pharmaceutical Institute Research Pharmaceutical Plant; from August 1993 to July 2000, he served as Chairman of Board and General Manager of Shanxi Zanhua Pharmaceutical Company; and since August 2000, he served as the Chairman of board of Shanxi Hongshan Pharmaceuticals Co., Ltd. He serves as a Board Director of Taxus Pharmaceuticals Holdings, Inc. He has been Director of Taxus Cardium Pharmaceuticals Group, Inc. since January 2015. Mr. Zhang graduated from Shanxi Province Chinese Herbs and Medicine School in 1985.
Insufficient data for Jiayue to compare compensation growth.
Jiayue's remuneration is lower than average for companies of similar size in United States of America.
Taxus Pharmaceuticals Holdings, Inc., a specialty retailer, sells dietary supplement products in New York. It offers vitamins, minerals, herbs, supplements, calcium, fibers, proteins, sports nutrition items, and other health and wellness products. The company was formerly known as Little Neck Health Connection, Inc. and changed its name to Taxus Pharmaceuticals Holdings, Inc. in September 2014. Taxus Pharmaceuticals Holdings, Inc. was founded in 2002 and is based in Little Neck, New York.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.